Business Context and Reporting Period
The submitted filing is Ambac Financial Group, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed February 27, 2024. The request metadata identifies “OCTAVE SPECIALTY GROUP INC,” but the filing text identifies the registrant as Ambac Financial Group, Inc. The filing reports three segments: Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance, and Insurance Distribution.
Legacy Financial Guarantee Insurance, including Ambac Assurance Corporation and Ambac UK, has been in run-off since 2008. Everspan provides specialty property and casualty program insurance, while Cirrata operates managing general agent, underwriting, brokerage and insurance distribution businesses.
Key Financial Metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenues and other income | $269 million | $505 million |
| Net income attributable to common stockholders | $4 million | $522 million |
| Diluted earnings per share | $0.18 | $11.31 |
| Adjusted net income | $93 million | $495 million |
| EBITDA | $107 million | $742 million |
| Operating cash flow | $200 million | $1.335 billion |
| Investing cash flow | $435 million | $866 million |
| Financing cash flow | $(423) million | $(2.163) billion |
| Total assets | $8.428 billion | $7.973 billion |
| Total stockholders’ equity | $1.415 billion | $1.305 billion |
Revenue included $78 million of net premiums earned, $51 million of commission income, $8 million of program fees and $140 million of net investment income. Net investment gains and derivative results were unfavorable at $(22) million and $(1) million, respectively.
Net income fell sharply because 2022 benefited from substantial litigation recoveries, favorable loss development related to Puerto Rico and RMBS matters, derivative gains and debt-extinguishment gains. The 2023 result included $156 million of general and administrative expense, $64 million of interest expense, $29 million of intangible amortization and a $7 million income-tax provision.
Segment Performance
| Segment | 2023 pretax income (loss) | 2022 pretax income (loss) | Selected 2023 metrics |
|---|---|---|---|
| Legacy Financial Guarantee Insurance | $17 million | $540 million | $26 million net premiums earned; $127 million net investment income; $69 million loss benefit |
| Specialty Property and Casualty Insurance | Approximately breakeven | $(6) million | $273 million gross written premiums; $80 million net written premiums; 106.5% combined ratio |
| Insurance Distribution | $7 million | $5 million | $231 million premiums placed; $51 million commission income; $22 million net commissions |
| Corporate and Other | $(13) million | $(14) million | $211 million standalone net assets excluding investments in subsidiaries |
Everspan’s loss and loss adjustment expense ratio increased to 70.7% from 65.4%, while its combined ratio improved materially from 156.5% to 106.5% but remained above 100%. Everspan had 23 programs with 19 MGA/Us at year-end and retained approximately 29% of 2023 gross written premium, including assumed premiums.
Material Changes Versus the Prior Comparable Period
- Net income attributable to common stockholders declined from $522 million to $4 million, primarily because 2022 contained unusually large litigation, restructuring and market-related benefits.
- Net premiums earned increased 38% to $78 million, driven by specialty P&C growth, partly offset by the run-off and de-risking of the legacy financial guarantee portfolio.
- Everspan gross written premiums increased 87% to $273 million from $146 million. Insurance Distribution premiums placed increased 70% to $231 million from $135 million.
- Net investment income increased to $140 million from $17 million, principally due to improved returns from pooled funds and higher yields on non-insured fixed-maturity securities.
- Derivative results declined from a $129 million gain to a $1 million loss. The economic hedge portfolio was fully exited in early 2023, leaving mainly legacy customer swaps and related hedges.
- Interest expense fell to $64 million from $168 million following the redemption of Tier 2 Notes and prior-year debt redemptions, but AAC continued to accrue interest on unpaid surplus notes.
- Ambac reduced net financial guarantee par outstanding by 14% to $19.541 billion from $22.613 billion, including a $2.069 billion quota-share reinsurance cession primarily involving military housing exposure.
- Total loss and loss adjustment expense reserves, net of subrogation recoverables and before reinsurance, increased to $756 million from $534 million, although the 2023 income statement recorded a $69 million legacy financial guarantee loss benefit.
- Total stockholders’ equity increased to $1.415 billion, supported primarily by $51 million of unrealized investment gains and $40 million of foreign-currency translation gains recorded in other comprehensive income.
Liquidity, Debt and Capital
AFG’s standalone net assets, excluding investments in subsidiaries, were $211 million at December 31, 2023, including $156 million of cash and short-term investments. Management stated that these assets were currently sufficient for holding-company liquidity needs. AFG has no outstanding holding-company debt, but its liquidity remains dependent in part on subsidiary distributions.
AAC’s ordinary dividend payments to AFG have been unavailable since 2008 and are not expected in 2024 without OCI approval. Everspan is not expected to pay dividends in the near term because of profitability and capital needs. Cirrata distributed $8 million to AFG in 2023.
| Debt metric | December 31, 2023 |
|---|---|
| AAC surplus notes, carrying value | $491 million |
| Ambac UK debt, carrying value | $17 million |
| Total non-VIE long-term debt | $508 million |
| Accrued interest payable | $475 million |
| VIE long-term debt | $2.967 billion |
OCI declined AAC’s request to pay the $519 million principal of surplus notes and accrued interest in June 2023. Interest continues to compound at 5.1%, and payments require OCI approval. The filing states that OCI may approve or deny payments in its sole discretion.
Ambac UK reported £489 million of shareholder funds and £535 million of cash and investments under UK accounting principles. Its Solvency II eligible capital was £430 million versus a £220 million regulatory capital requirement, producing a £210 million surplus.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide quantitative earnings or revenue guidance. Management’s strategy is to grow specialty P&C and insurance distribution, pursue acquisitions and de novo MGA/Us, and actively de-risk and monetize the legacy financial guarantee businesses. Ambac and its advisors were discussing strategic alternatives for AAC and Ambac UK, with discussions expected to be completed in 2024; no transaction was assured.
- Regulatory restrictions: AAC’s dividends, debt payments, investment-policy changes, affiliate transactions and certain strategic actions require OCI approval or non-disapproval under the Settlement Agreement and the February 2024 Stipulation and Order.
- Legacy portfolio risk: Loss reserves depend on assumptions regarding defaults, severity, recoveries, commutations, restructuring and discount rates. Management disclosed potential stress-case increases of approximately $55 million for certain structured finance exposures, $125 million for public finance exposures and approximately $330 million for other credits, including Ambac UK; actual losses could exceed these scenarios.
- Financial guarantee concentration: International finance represented $8.664 billion, or 44%, of net par outstanding; the United Kingdom represented $7.502 billion. The ten largest exposures represented 31% of total net par.
- Specialty P&C underwriting: Everspan remains in an early growth phase and faces catastrophe, social inflation, reserve adequacy, pricing, MGA/TPA performance and reinsurance availability risks. Its combined ratio remained above 100% in 2023.
- Reinsurance counterparty risk: Reinsurance recoverables on paid and unpaid losses were $195 million, with $128 million of uncollateralized exposure. The top three reinsurers represented 74% of recoverables.
- Litigation and contingencies: Material matters include military housing litigation, National Collegiate student-loan trust litigation, Puerto Rico-related matters and CFPB litigation. The filing states that legal accruals for probable and estimable losses were not material, but potential unfavorable outcomes could materially affect results or liquidity.
- Investments and market risk: Non-VIE investments totaled $2.664 billion. A hypothetical 100-basis-point rate increase would reduce the fair value of fixed-maturity investments by approximately $50 million, while a 20% strengthening of the U.S. dollar would reduce the fair value of foreign-currency investments by approximately $93 million.
- Tax assets: The company reported approximately $3.4 billion of U.S. federal NOLs and maintained a full valuation allowance against related deferred tax assets because future taxable income is uncertain.
- Unusual prior-year items: 2022 results included the $1.840 billion Bank of America settlement, the $140 million Nomura settlement received in January 2023, Puerto Rico restructuring effects, $129 million of derivative gains and $81 million of debt-extinguishment gains.
Important Facts for Investors to Verify
- Confirm that the filing entity is Ambac Financial Group, Inc., not the company named in the request metadata.
- Reconcile 2023 GAAP net income of $4 million with adjusted net income of $93 million and identify which adjustments are recurring versus nonrecurring.
- Assess whether Everspan can achieve underwriting profitability as its 106.5% combined ratio improves toward or below 100%.
- Evaluate AAC’s ability to generate recoveries, repay or restructure surplus notes and obtain OCI approval for future payments or distributions.
- Review the assumptions supporting the $756 million net loss reserve balance and the disclosed stress-case exposures.
- Analyze reinsurance collateral, counterparty concentration and the $128 million of uncollateralized recoverable exposure.
- Track the outcome of pending litigation and any regulatory developments involving AAC, Ambac UK, Everspan or the MGA/Us.
- Verify the sustainability of 2023 investment returns, particularly pooled-fund gains, and the effect of interest-rate and foreign-currency movements.
- Confirm future capital requirements for Everspan and the extent to which growth may require additional AFG capital contributions.